Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Third-line Treatment”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05438706
What this trial is testing

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Fudan University 70
Testing effectiveness (Phase 2)Ended earlyNCT04863248
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Who this might be right for
Metastatic Non-Small Cell Lung CancerNSCLCLung Cancer
G1 Therapeutics, Inc. 10
Testing effectiveness (Phase 2)Study completedNCT01553539
What this trial is testing

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Who this might be right for
Bone CancerChondrosarcomaClear Cell Sarcoma of the Kidney+9 more
Wake Forest University Health Sciences 20
Testing effectiveness (Phase 2)Looking for participantsNCT03886311
What this trial is testing

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Who this might be right for
Sarcoma
Sarcoma Oncology Research Center, LLC 200
Testing effectiveness (Phase 2)Looking for participantsNCT06356714
What this trial is testing

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Who this might be right for
Colorectal CancerColorectal Neoplasms
Sun Jing 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT01843374
What this trial is testing

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Who this might be right for
Unresectable Pleural or Peritoneal Malignant Mesothelioma
MedImmune LLC 571
Not applicableStudy completedNCT01225406
What this trial is testing

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Who this might be right for
This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy
The HIV Netherlands Australia Thailand Research Collaboration 56
Testing effectiveness (Phase 2)Looking for participantsNCT06685276
What this trial is testing

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Dai, Guanghai 46
Testing effectiveness (Phase 2)UnknownNCT05970705
What this trial is testing

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

Who this might be right for
Metastatic Colorectal Cancer
Fudan University 101
Not applicableNot Yet RecruitingNCT05810142
What this trial is testing

Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

Who this might be right for
Third-line TreatmentDvanced Duodenal AdenocarcinomaFurquinelone Combined With Sintilimab
RenJi Hospital 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT07669610
What this trial is testing

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)
Fudan University 140
Testing effectiveness (Phase 2)WithdrawnNCT02522910
What this trial is testing

An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC (Non-Small Cell Lung Cancer)
Yonsei University
Testing effectiveness (Phase 2)Study completedNCT00798720
What this trial is testing

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non Small Cell Lung
University of Wisconsin, Madison 18
Testing effectiveness (Phase 2)UnknownNCT02296203
What this trial is testing

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 27
Very early researchNot Yet RecruitingNCT07458919
What this trial is testing

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Who this might be right for
Lung Cancer
Fuzhou General Hospital 94
Not applicableStudy completedNCT05619978
What this trial is testing

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Who this might be right for
Chronic Myeloid Leukemia
Novartis Pharmaceuticals 200
Testing effectiveness (Phase 2)Study completedNCT03254654
What this trial is testing

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Who this might be right for
Advanced Triple-Negative Breast Cancer
Fudan University 66
Very early researchStudy completedNCT05463822
What this trial is testing

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

Who this might be right for
Overactive BladderBladder, OveractiveUrge Incontinence+2 more
Stanford University 15
Testing effectiveness (Phase 2)UnknownNCT04803851
What this trial is testing

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Who this might be right for
AnlotinibAnti-PD-1 AntibodyAdvanced Pancreatic Cancer
Peking Union Medical College Hospital 29
Testing effectiveness (Phase 2)Study completedNCT04953962
What this trial is testing

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer Stage IV
CanBas Co. Ltd. 36
Next Page